These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 16053341)

  • 1. Optimizing administration of bisphosphonates in women with postmenopausal osteoporosis.
    Rackoff PJ; Sebba A
    Treat Endocrinol; 2005; 4(4):245-51. PubMed ID: 16053341
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical pharmacology of potent new bisphosphonates for postmenopausal osteoporosis.
    Chapurlat RD
    Treat Endocrinol; 2005; 4(2):115-25. PubMed ID: 15783248
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy, side effects and route of administration are more important than frequency of dosing of anti-osteoporosis treatments in determining patient adherence: a critical review of published articles from 1970 to 2009.
    Lee S; Glendenning P; Inderjeeth CA
    Osteoporos Int; 2011 Mar; 22(3):741-53. PubMed ID: 20589368
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risedronate: a new oral bisphosphonate.
    Umland EM; Boyce EG
    Clin Ther; 2001 Sep; 23(9):1409-21. PubMed ID: 11589256
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tolerability of different dosing regimens of bisphosphonates for the treatment of osteoporosis and malignant bone disease.
    Bobba RS; Beattie K; Parkinson B; Kumbhare D; Adachi JD
    Drug Saf; 2006; 29(12):1133-52. PubMed ID: 17147460
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bisphosphonate therapy.
    Licata AA
    Am J Med Sci; 1997 Jan; 313(1):17-22. PubMed ID: 9001162
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug insight: Bisphosphonates for postmenopausal osteoporosis.
    Chapurlat RD; Delmas PD
    Nat Clin Pract Endocrinol Metab; 2006 Apr; 2(4):211-9; quiz following 238. PubMed ID: 16932286
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A meta-analysis characterizing the dose-response relationships for three oral nitrogen-containing bisphosphonates in postmenopausal women.
    Yates J
    Osteoporos Int; 2013 Jan; 24(1):253-62. PubMed ID: 23100120
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis.
    Cramer JA; Amonkar MM; Hebborn A; Altman R
    Curr Med Res Opin; 2005 Sep; 21(9):1453-60. PubMed ID: 16197664
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bisphosphonates.
    Diez-Perez A
    Maturitas; 2002 Aug; 43 Suppl 1():S19-26. PubMed ID: 12361885
    [No Abstract]   [Full Text] [Related]  

  • 11. Use of highly potent bisphosphonates in the treatment of osteoporosis.
    McClung M
    Curr Osteoporos Rep; 2003 Dec; 1(3):116-22. PubMed ID: 16036074
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of alendronate and risedronate in preventing and treating osteoporosis.
    Peters ML; Leonard M; Licata AA
    Cleve Clin J Med; 2001 Nov; 68(11):945-51. PubMed ID: 11718433
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bisphosphonates for osteoporosis.
    Drug Ther Bull; 2001 Sep; 39(9):68-72. PubMed ID: 11586803
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of intravenously administered ibandronate in postmenopausal Korean women with insufficient response to orally administered bisphosphonates.
    Bae SJ; Kim BJ; Lim KH; Lee SH; Kim HK; Kim GS; Koh JM
    J Bone Miner Metab; 2012 Sep; 30(5):588-95. PubMed ID: 22610063
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of osteoporosis with bisphosphonates.
    Watts NB
    Rheum Dis Clin North Am; 2001 Feb; 27(1):197-214. PubMed ID: 11285996
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of bisphosphonates in reducing fracture risk in postmenopausal osteoporosis.
    Bilezikian JP
    Am J Med; 2009 Feb; 122(2 Suppl):S14-21. PubMed ID: 19187808
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bisphosphonates in the treatment of osteoporosis. Principles and efficacy.
    Papapoulos SE
    Ann Med Interne (Paris); 2000 Oct; 151(6):504-10. PubMed ID: 11104931
    [No Abstract]   [Full Text] [Related]  

  • 18. Optimizing the management of postmenopausal osteoporosis with bisphosphonates: the emerging role of intermittent therapy.
    Miller PD
    Clin Ther; 2005 Apr; 27(4):361-76. PubMed ID: 15922811
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Determinants of non-compliance with bisphosphonates in women with postmenopausal osteoporosis.
    Penning-van Beest FJ; Erkens JA; Olson M; Herings RM
    Curr Med Res Opin; 2008 May; 24(5):1337-44. PubMed ID: 18380910
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of daily and intermittent use of ibandronate on bone mass and bone turnover in postmenopausal osteoporosis: a review of three phase II studies.
    Schimmer RC; Bauss F
    Clin Ther; 2003 Jan; 25(1):19-34. PubMed ID: 12637110
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.